cantly lower
among the patients undergoing CEA (2.6%þ0.7% for
CEA and 5.6%þ1.0% for transfemoral CAS; P ¼ .006). A

Journal of Vascular Surgery

AbuRahma et al

43S

Volume 75, Number 1S

2020 Cochrane Review showed that in symptomatic patients, transfemoral CAS was